Genmab A/S (GMAB)
51.37
-0.37
(-0.72%)
USD |
NASDAQ |
Nov 13, 16:00
52.12
+0.74
(+1.45%)
After-Hours: 06:24
Genmab Enterprise Value : 34.93B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 34.93B |
| November 12, 2026 | 35.16B |
| November 11, 2026 | 36.47B |
| November 10, 2026 | 36.59B |
| November 09, 2026 | 37.65B |
| November 06, 2026 | 36.32B |
| November 05, 2026 | 35.77B |
| November 04, 2026 | 37.23B |
| November 03, 2026 | 37.48B |
| November 02, 2026 | 37.11B |
| October 30, 2026 | 38.43B |
| October 29, 2026 | 38.08B |
| October 28, 2026 | 38.57B |
| October 27, 2026 | 30.81B |
| October 26, 2026 | 30.82B |
| October 23, 2026 | 30.27B |
| October 22, 2026 | 27.94B |
| October 21, 2026 | 27.67B |
| October 20, 2026 | 27.36B |
| October 19, 2026 | 27.01B |
| October 16, 2026 | 26.09B |
| October 15, 2026 | 26.60B |
| October 14, 2026 | 26.02B |
| October 13, 2026 | 25.83B |
| October 12, 2026 | 26.32B |
| Date | Value |
|---|---|
| October 09, 2026 | 26.13B |
| October 08, 2026 | 25.51B |
| October 07, 2026 | 25.88B |
| October 06, 2026 | 26.58B |
| October 05, 2026 | 27.00B |
| October 02, 2026 | 24.71B |
| October 01, 2026 | 24.58B |
| September 30, 2026 | 25.28B |
| September 29, 2026 | 25.01B |
| September 28, 2026 | 24.88B |
| September 25, 2026 | 24.86B |
| September 24, 2026 | 24.56B |
| September 23, 2026 | 24.52B |
| September 22, 2026 | 24.80B |
| September 21, 2026 | 24.48B |
| September 18, 2026 | 24.51B |
| September 17, 2026 | 24.39B |
| September 16, 2026 | 24.31B |
| September 15, 2026 | 24.16B |
| September 14, 2026 | 23.26B |
| September 11, 2026 | 23.16B |
| September 10, 2026 | 23.01B |
| September 09, 2026 | 23.50B |
| September 08, 2026 | 23.79B |
| September 04, 2026 | 23.83B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 591.64B |
| Incyte Corp. | 20.86B |
| Ascendis Pharma A/S | 17.48B |
| Zealand Pharma A/S | 407.51M |
| Bavarian Nordic A/S | 2.199B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 341.65M |
| Revenue (Quarterly) | 1.186B |
| Total Expenses (Quarterly) | 844.13M |
| EPS Diluted (Quarterly) | 0.5475 |
| Gross Profit Margin (Quarterly) | 90.31% |
| Profit Margin (Quarterly) | 28.81% |
| Earnings Yield | 2.27% |
| Operating Earnings Yield | 4.01% |
| Normalized Earnings Yield | 2.835 |